Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs

Reuters2025-12-26

Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs

Zenas Biopharma Inc. has released a corporate presentation detailing its current pipeline and development plans in the autoimmune and inflammatory disease space. The company highlights two late-stage franchise programs targeting four indications, as well as two early-stage programs with potential best-in-class profiles. Key assets include obexelimab, advancing in late-stage clinical trials for indications such as IgG4-related disease and multiple sclerosis, and orelabrutinib, a BTK inhibitor under investigation for primary and secondary progressive multiple sclerosis. Additional early-stage candidates, ZB021 and ZB022, are expected to enter Phase 1 trials in 2026. The executive team’s extensive experience in biopharmaceutical development and commercialization is also noted. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on December 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2594294291?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-26 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594294291","market":"us","top_or_hot":-1,"title":"Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zenas Biopharma Inc. has released a corporate presentation detailing its current pipeline and development plans in the autoimmune and inflammatory disease space. The company highlights two late-stage franchise programs targeting four indications, as well as two early-stage programs with potential best-in-class profiles. Key assets include obexelimab, advancing in late-stage clinical trials for indications such as IgG4-related disease and multiple sclerosis, and orelabrutinib, a BTK inhibitor under investigation for primary and secondary progressive multiple sclerosis. Additional early-stage candidates, ZB021 and ZB022, are expected to enter Phase 1 trials in 2026. The executive team’s extensive experience in biopharmaceutical development and commercialization is also noted. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on December 26, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-26 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Zenas Biopharma Inc. has released a corporate presentation detailing its current pipeline and development plans in the autoimmune and inflammatory disease space. The company highlights two late-stage franchise programs targeting four indications, as well as two early-stage programs with potential best-in-class profiles. Key assets include obexelimab, advancing in late-stage clinical trials for indications such as IgG4-related disease and multiple sclerosis, and orelabrutinib, a BTK inhibitor under investigation for primary and secondary progressive multiple sclerosis. Additional early-stage candidates, ZB021 and ZB022, are expected to enter Phase 1 trials in 2026. The executive team’s extensive experience in biopharmaceutical development and commercialization is also noted. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on December 26, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZBIO","symbol_name":"Zenas BioPharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251226:nNDL7Vcn6Z:1","article_id":"2594294291","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594294291","pubTimestamp":1766760584,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zenas Biopharma Inc. has released a corporate presentation detailing its current pipeline and development plans in the autoimmune and inflammatory disease space. The company highlights two late-stage franchise programs targeting four indications, as well as two early-stage programs with potential best-in-class profiles. Key assets include obexelimab, advancing in late-stage clinical trials for indications such as IgG4-related disease and multiple sclerosis, and orelabrutinib, a BTK inhibitor under investigation for primary and secondary progressive multiple sclerosis. Additional early-stage candidates, ZB021 and ZB022, are expected to enter Phase 1 trials in 2026. The executive team’s extensive experience in biopharmaceutical development and commercialization is also noted. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZBIO":"Zenas BioPharma Inc.","BK4139":"生物科技"},"translate_title":"Zenas Biopharma公布管道更新，重点介绍后期自身免疫项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBIO":0.9},"content_text":"Zenas Biopharma Unveils Pipeline Update Highlighting Late-Stage Autoimmune Programs\n    \n\n        Zenas Biopharma Inc. has released a corporate presentation detailing its current pipeline and development plans in the autoimmune and inflammatory disease space. The company highlights two late-stage franchise programs targeting four indications, as well as two early-stage programs with potential best-in-class profiles. Key assets include obexelimab, advancing in late-stage clinical trials for indications such as IgG4-related disease and multiple sclerosis, and orelabrutinib, a BTK inhibitor under investigation for primary and secondary progressive multiple sclerosis. Additional early-stage candidates, ZB021 and ZB022, are expected to enter Phase 1 trials in 2026. The executive team’s extensive experience in biopharmaceutical development and commercialization is also noted. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on December 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594294291","isCrawlerRequest":true}